Stem cell mobilization · 11 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Plerixafor and G-CSF Variant #01 Partial | — | R 413 930 | — | — | — | ~1 | ~R 413 930 indirect | — |
EAR and G-CSF Variant #01 | — | R 69 972 | — | — | — | ~1 | ~R 69 972 indirect | — |
IGEV and G-CSF Variant #01 | — | R 21 643 | — | — | — | ~1 | ~R 21 643 indirect | — |
Cytarabine, Ifosfamide, G-CSF Variant #01 Partial | — | R 13 144 | — | — | — | ~1 | ~R 13 144 indirect | — |
Cytarabine and G-CSF Variant #02 Partial | — | R 12 419 | — | — | — | ~1 | ~R 12 419 indirect | — |
Cytarabine and Etoposide (CYVE) and G-CSF Variant #01 | — | R 11 750 | — | — | — | ~1 | ~R 11 750 indirect | — |
DexaBEAM and G-CSF Variant #01 Partial | — | R 5 009 | — | — | — | ~1 | ~R 5 009 indirect | — |
DCEP and G-CSF Variant #01 | — | R 2 157 | — | — | — | ~2 | ~R 4 314 indirect | — |
CAD and G-CSF Variant #01 | — | R 1 274 | — | — | — | ~1 | ~R 1 274 indirect | — |
Cyclophosphamide and G-CSF Variant not yet assigned - class-based regimen Partial | — | R 376 | — | — | — | ~1 | ~R 376 indirect | — |
Motixafortide and G-CSF Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
11 of 11 regimens shown